Establishment Labs (NASDAQ:ESTA) Price Target Increased to $65.00 by Analysts at BTIG Research

Establishment Labs (NASDAQ:ESTA - Free Report) had its target price raised by BTIG Research from $62.00 to $65.00 in a research report sent to investors on Monday morning, Benzinga reports. BTIG Research currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the company. Stephens restated an overweight rating and issued a $68.00 price target on shares of Establishment Labs in a report on Wednesday, August 7th. Citigroup increased their target price on Establishment Labs from $45.00 to $50.00 and gave the stock a neutral rating in a research note on Tuesday, October 1st. Finally, JPMorgan Chase & Co. cut their price target on shares of Establishment Labs from $61.00 to $50.00 and set an overweight rating on the stock in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $58.83.

Establishment Labs Trading Up 3.6 %

Shares of ESTA stock traded up $1.45 on Monday, reaching $41.28. The company had a trading volume of 314,767 shares, compared to its average volume of 378,879. The company has a 50-day moving average of $42.46 and a 200-day moving average of $46.82. Establishment Labs has a 12 month low of $16.96 and a 12 month high of $60.12. The stock has a market cap of $1.14 billion, a PE ratio of -13.31 and a beta of 1.20. The company has a current ratio of 4.44, a quick ratio of 2.91 and a debt-to-equity ratio of 4.30.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. The firm had revenue of $44.12 million during the quarter, compared to analyst estimates of $43.10 million. During the same quarter last year, the business posted ($0.65) earnings per share. The company's revenue for the quarter was down 9.2% on a year-over-year basis. On average, equities analysts forecast that Establishment Labs will post -2.27 earnings per share for the current year.

Institutional Trading of Establishment Labs

Institutional investors have recently made changes to their positions in the business. Capital Research Global Investors bought a new stake in Establishment Labs during the 1st quarter worth about $45,888,000. William Blair Investment Management LLC acquired a new position in Establishment Labs during the first quarter valued at approximately $21,415,000. First Turn Management LLC bought a new position in shares of Establishment Labs in the second quarter valued at $16,812,000. Sofinnova Investments Inc. increased its holdings in Establishment Labs by 204.1% during the second quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company's stock worth $19,505,000 after buying an additional 288,082 shares during the last quarter. Finally, Divisadero Street Capital Management LP bought a new stake in Establishment Labs during the second quarter worth $5,829,000. Institutional investors own 72.91% of the company's stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.